Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Short Interest Up 26.7% in December

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 615,400 shares, a growth of 26.7% from the December 15th total of 485,600 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 6,154.0 days.

Analysts Set New Price Targets

A number of research firms recently commented on RCDTF. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a "strong sell" rating in a report on Tuesday, October 22nd. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a "hold" rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

Shares of OTCMKTS RCDTF remained flat at $55.54 during mid-day trading on Friday. The firm's 50 day moving average is $53.19 and its 200-day moving average is $52.48. Recordati Industria Chimica e Farmaceutica has a 52 week low of $52.25 and a 52 week high of $52.25.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.